Holocene Advisors LP Acquires 135,367 Shares of Jazz Pharmaceuticals PLC $JAZZ

Holocene Advisors LP lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 28.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 605,109 shares of the specialty pharmaceutical company’s stock after buying an additional 135,367 shares during the quarter. Holocene Advisors LP’s holdings in Jazz Pharmaceuticals were worth $79,753,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares during the period. Capital World Investors grew its holdings in Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock worth $336,731,000 after acquiring an additional 10,345 shares during the period. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after acquiring an additional 87,576 shares during the period. Ameriprise Financial Inc. raised its position in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after purchasing an additional 145,865 shares during the period. 89.14% of the stock is owned by institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the transaction, the executive vice president owned 56,862 shares of the company’s stock, valued at $10,892,484.72. This represents a 49.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president directly owned 28,728 shares of the company’s stock, valued at $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 68,015 shares of company stock valued at $13,037,486 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on JAZZ shares. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Finally, Needham & Company LLC upped their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $214.38.

Jazz Pharmaceuticals Trading Up 1.9%

JAZZ opened at $182.02 on Tuesday. The stock has a market capitalization of $11.21 billion, a P/E ratio of -30.49, a P/E/G ratio of 0.32 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $198.00. The firm’s fifty day simple moving average is $172.48 and its 200 day simple moving average is $156.82. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company earned $6.51 EPS. The company’s revenue was up 8.1% on a year-over-year basis. As a group, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.